<DOC>
	<DOC>NCT00395018</DOC>
	<brief_summary>The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.</brief_summary>
	<brief_title>Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Patients receiving orthotopic liver transplant (OLT) due to endstage liver disease because of chronic HBV infection, with HBVDNA &lt; 172 IU/mL (approximately &lt; 1000 copies/mL) prior to liver transplant Must have detectable hepatitis B surface antigen (HBsAg) at screening and for at least 24 weeks prior to screening Patients with hepatocellular carcinoma with evidence of extrahepatic spread, multiple tumors ≥ 6.5 cm in diameter or there is up to three nodules ≥ 4.5 cm in diameter and total tumor diameter is ≥ 8 cm Coinfection with human immunodeficiency virus (HIV), cytomegalovirus (CMV), EpsteinBarr virus (EBV) or hepatitis C virus (HCV)</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Chronic Hepatitis B Virus, Liver Transplant</keyword>
</DOC>